帕博西尼(Palbociclib)研究报告.pdf

《帕博西尼(Palbociclib)研究报告.pdf》由会员上传分享，免费在线阅读，更多相关内容在教育资源-天天文库。

1、帕博西尼研究报告Copyrights©2016Pharmacodia(Beijing)Co.,LTD.Allrightsreserved二零一六年九月目录摘要..........................................................................................................................51.PALBOCICLIB概述........................................................

2、...................................81.1PALBOCICLIB基本信息...................................................................................81.2PALBOCICLIB全球上市信息...........................................................................91.3PALBOCICLIB国内注册信息...................

3、........................................................91.4临床药理学综述...........................................................................................151.5临床试验综述...............................................................................................172.PALBO

4、CICLIB专利及合成工艺分析.............................................................212.1PALBOCICLIB专利分析.................................................................................212.2PALBOCICLIB合成路线............................................................................

5、.....452.3PALBOCICLIBCMC概括...............................................................................523.PALBOCICLIB适应症概述.............................................................................553.1乳腺癌简介.............................................................

6、......................................553.2晚期乳腺癌...................................................................................................563.3晚期乳腺癌的治疗........................................................................................583.4晚期乳腺癌流行病学研究.........

7、...................................................................684.PALBOCICLIB市场调研.................................................................................744.1全球乳腺癌市场规模...................................................................................744.2PALB

8、OCICLIB全球销量分析.........................................................................764